A detailed history of Twinbeech Capital LP transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Twinbeech Capital LP holds 69,283 shares of DVAX stock, worth $893,750. This represents 0.02% of its overall portfolio holdings.

Number of Shares
69,283
Previous 172,297 59.79%
Holding current value
$893,750
Previous $1.93 Million 60.13%
% of portfolio
0.02%
Previous 0.04%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.05 - $11.61 $1.04 Million - $1.2 Million
-103,014 Reduced 59.79%
69,283 $771,000
Q2 2024

Aug 14, 2024

SELL
$10.73 - $12.58 $118,759 - $139,235
-11,068 Reduced 6.04%
172,297 $1.93 Million
Q1 2024

May 15, 2024

SELL
$11.7 - $14.98 $502,257 - $643,061
-42,928 Reduced 18.97%
183,365 $2.28 Million
Q4 2023

Feb 14, 2024

BUY
$13.09 - $14.98 $2.96 Million - $3.39 Million
226,293 New
226,293 $3.16 Million
Q4 2022

Feb 14, 2023

BUY
$10.27 - $13.29 $2.18 Million - $2.82 Million
212,203 New
212,203 $2.26 Million

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.63B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Twinbeech Capital LP Portfolio

Follow Twinbeech Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Twinbeech Capital LP with notifications on news.